CYCN

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Cyclerion Therapeutics Inc

NASDAQ | CYCN

2.13

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 23, 2025)

$6.91M

Market Cap

-

P/E Ratio

-0.69

EPS

$9.47

52 Week High

$1.27

52 Week Low

HEALTHCARE

Sector

CYCN Chart

Recent Chart
Price Action

CYCN Technicals

Tags:

CYCN Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $2M
Total Revenue $2M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$3.6M
Selling General And Administrative $5.3M
Research And Development $286K
Operating Expenses $5.6M
Investment Income Net -
Net Interest Income $208K
Interest Income $208K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$3.1M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$3.1M
Comprehensive Income Net Of Tax -
Ebit -$3.6M
Ebitda -$3.6M
Net Income -$3.1M

Revenue & Profitability

Earnings Performance

CYCN Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $9.6M
Total Current Assets $4.2M
Cash And Cash Equivalents At Carrying Value $3.2M
Cash And Short Term Investments $3.2M
Inventory -
Current Net Receivables $556K
Total Non Current Assets $5.4M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $5.4M
Short Term Investments -
Other Current Assets $437K
Other Non Current Assets -
Total Liabilities $725K
Total Current Liabilities $725K
Current Accounts Payable $390K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $335K
Other Non Current Liabilities -
Total Shareholder Equity $8.9M
Treasury Stock -
Retained Earnings -$267M
Common Stock -
Common Stock Shares Outstanding $2.5M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$4.3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $0
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$3.1M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $2M
Total Revenue $2M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$3.6M
Selling General And Administrative $5.3M
Research And Development $286K
Operating Expenses $5.6M
Investment Income Net -
Net Interest Income $208K
Interest Income $208K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$3.1M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$3.1M
Comprehensive Income Net Of Tax -
Ebit -$3.6M
Ebitda -$3.6M
Net Income -$3.1M

CYCN News

CYCN Profile

Cyclerion Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for serious central nervous system (CNS) disorders. The company leverages its proprietary technology platform to develop a promising pipeline aimed at addressing significant unmet medical needs, particularly in cognitive impairment and related CNS diseases. Cyclerion's focus on advancing treatment options underscores its strategic positioning within the biopharmaceutical sector, making it an attractive investment opportunity for institutional investors interested in the evolving landscape of neurotherapeutics.

YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
BURU
-5.27%
$0.34
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
INTC
+3.35%
$38.15
MSAI
+101.73%
$1.35
ADAP
-3.44%
$0.07
AAL
+5.62%
$12.77
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
BITF
+4.39%
$4.11
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
IONQ
+7.06%
$59.37
DNN
+0.18%
$2.72
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
JOBY
+1.29%
$15.67
BBD
+1.51%
$3.35
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
ADD
-25.47%
$0.05
BTG
+0.38%
$5.23
VLY
+4.24%
$10.56
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
PFE
-0.20%
$24.67
TNGX
-12.24%
$7.60
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
UUUU
-6.50%
$21.26
CIFR
+7.10%
$17.25
WBD
+3.50%
$21.25
ONDS
+5.56%
$7.11
AMZN
+1.44%
$221.09
HPE
+0.43%
$23.19
NIO
+0.73%
$6.89
IREN
+7.77%
$55.86
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
PBR
+0.93%
$11.84
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
RIVN
+1.31%
$13.09
BAC
+1.29%
$51.76
BTE
+5.28%
$2.39
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.58%
$7.78
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
NAKA
+10.41%
$0.79
SMR
+8.17%
$37.56
YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
BURU
-5.27%
$0.34
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
INTC
+3.35%
$38.15
MSAI
+101.73%
$1.35
ADAP
-3.44%
$0.07
AAL
+5.62%
$12.77
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
BITF
+4.39%
$4.11
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
IONQ
+7.06%
$59.37
DNN
+0.18%
$2.72
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
JOBY
+1.29%
$15.67
BBD
+1.51%
$3.35
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
ADD
-25.47%
$0.05
BTG
+0.38%
$5.23
VLY
+4.24%
$10.56
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
PFE
-0.20%
$24.67
TNGX
-12.24%
$7.60
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
UUUU
-6.50%
$21.26
CIFR
+7.10%
$17.25
WBD
+3.50%
$21.25
ONDS
+5.56%
$7.11
AMZN
+1.44%
$221.09
HPE
+0.43%
$23.19
NIO
+0.73%
$6.89
IREN
+7.77%
$55.86
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
PBR
+0.93%
$11.84
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
RIVN
+1.31%
$13.09
BAC
+1.29%
$51.76
BTE
+5.28%
$2.39
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.58%
$7.78
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
NAKA
+10.41%
$0.79
SMR
+8.17%
$37.56
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.